From Casetext: Smarter Legal Research

United States v. Novartis Pharm. Corp.

United States District Court, S.D. New York
Sep 14, 2022
13 CIVIL 3700 (KMW) (S.D.N.Y. Sep. 14, 2022)

Opinion

13 CIVIL 3700 (KMW)

09-14-2022

UNITED STATES OF AMERICA; the States of CALIFORNIA, COLORADO, CONNECTICUT, DELAWARE, FLORIDA, GEORGIA, HAWAII, ILLINOIS, INDIANA, IOWA, LOUISIANA, MASSACHUSETTS, MICHIGAN, MINNESOTA, MONTANA, NEVADA, NEW JERSEY, NEW MEXICO, NEW YORK, NORTH CAROLINA, OKLAHOMA, RHODE ISLAND, TENNESSEE, TEXAS, VIRGINIA, WASHINGTON and WISCONSIN, the DISTRICT OF COLUMBIA, THE CITY OF CHICAGO and THE CITY OF NEW YORK ex rel. STEVEN M. CAMBURN, Plaintiffs and Relator, v. NOVARTIS PHARMACEUTICALS CORPORATION, Defendant.


JUDGMENT

It is hereby ORDERED, ADJUDGED AND DECREED: That for the reasons stated in the Court's Opinion and Order dated September 13, 2022, Novartis' motion to dismiss pursuant to Rules 12(b)(6) and 9(b) is GRANTED, and the TAC is dismissed with prejudice; accordingly, the case is closed.


Summaries of

United States v. Novartis Pharm. Corp.

United States District Court, S.D. New York
Sep 14, 2022
13 CIVIL 3700 (KMW) (S.D.N.Y. Sep. 14, 2022)
Case details for

United States v. Novartis Pharm. Corp.

Case Details

Full title:UNITED STATES OF AMERICA; the States of CALIFORNIA, COLORADO, CONNECTICUT…

Court:United States District Court, S.D. New York

Date published: Sep 14, 2022

Citations

13 CIVIL 3700 (KMW) (S.D.N.Y. Sep. 14, 2022)